Investor

One Drop recently announced the acquisition of Sano's assets, IP and a portion of its staff.

Also: RDMD locks in $14M for rare disease therapy research; VIDA Diagnostics raises $11M for AI lunch imaging analysis.

Alongside the purchase of Amblyotech, the pharma company announced upcoming collaborations with major video game publisher Ubisoft and McGill University.

In this COVID-19 era, the need for health and care systems to become agile and change is very real. 

The new tool will be combined with Biofourmis' Biovitals platform and be able to give insights to cancer patients at home. 

Also: Mercom's Q1 2020 digital health funding report; Fitbit, Scripps, Stanford collaborate on COVID-19 detection research.

Just as it's doing with nearly every facet of society around the world, the COVID-19 crisis will radically transform approaches with patient engagement and pop health. From telemedicine and remote patient monitoring to AI and advanced analytics, healthcare was already in the midst of big changes in how it manages the health of patient populations. Now, in a new era where the pandemic is upending old assumptions, the stakes are even higher. This month, we look at how approaches to treating COVID-19 and other illnesses are shifting in this new era.  

Many are anticipating greater adoption of digital health services and more favorable regulatory and reimbursement environments, according to a recent poll sampling 513 digital health and adjacent companies.

Also: Datos Health ties off $7 million in Series A funding; Wellthy Therapeutics collects $4 million in pre-Series A; Lifesprk fleshes out tech with $16.1 million.

Amid COVID-19, a new 1,000-person survey suggests high demand for remote health services.